Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.3M | $21.3M | $23.3M | $19.8M | $5.80M | — | $0.00 | $68.0K | $582K | — |
| Revenue growth | — | -4.7% | 9.7% | -15.1% | -70.7% | — | — | — | 755.9% | — |
| Gross profit | — | — | — | — | — | — | $0.00 | -$168K | $486K | — |
| Gross margin | — | — | — | — | — | — | — | -247.1% | 83.5% | — |
| Operating income | -$2.28M | -$1.40M | $203K | -$1.76M | -$26.5M | -$114M | -$33.2M | -$21.1M | -$15.7M | -$9.32M |
| Operating margin | -10.2% | -6.6% | 0.9% | -8.9% | -456.7% | — | — | -31080.9% | -2693.1% | — |
| Net income | -$2.92M | -$1.08M | -$259K | -$2.05M | -$26.5M | -$123M | -$24.6M | -$21.7M | -$44.5M | -$14.1M |
| Net margin | -13.1% | -5.1% | -1.1% | -10.3% | -457.4% | — | — | -31864.7% | -7652.7% | — |
| EPS (diluted) | -$1.54 | -$0.45 | -$0.10 | -$0.72 | -$1.51 | -$56.61 | -$8.06 | -$4.08 | -$48.96 | -$2.24 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $23.0K | $549K | $1.36M | $2.74M | -$8.10M | -$23.5M | -$21.0M | -$20.4M | -$15.8M | -$7.02M |
| Capital expenditures | $427K | $728K | $648K | $128K | $39.0K | $154K | $297K | $19.0K | $369K | $37.0K |
| Free cash flow | -$404K | -$179K | $717K | $2.62M | -$8.14M | -$23.6M | -$21.3M | -$20.4M | -$16.2M | -$7.05M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.69M | $3.38M | $2.79M | $5.10M | $1.63M | $17.0M | $15.5M | $11.7M | $1.73M | $1.88M |
| Total assets | $16.7M | $16.6M | $14.9M | $14.1M | $13.8M | $31.5M | $22.3M | $49.1M | $5.27M | $5.83M |
| Total liabilities | $12.6M | $11.0M | $7.95M | $9.03M | $25.4M | $6.02M | $10.2M | $46.9M | $3.57M | $3.43M |
| Long-term debt | $8.11M | $5.12M | $3.75M | — | $532K | — | — | — | — | — |
| Shareholders' equity | $4.07M | $5.54M | $6.92M | $9.74M | $7.66M | $25.5M | $12.1M | $2.23M | $1.70M | $2.40M |
| Retained earnings | -$128M | -$129M | -$129M | -$131M | -$37.4M | -$141M | -$165M | -$187M | -$232M | -$246M |
| Shares (wtd avg diluted) | 92.4M | 2.52M | 2.88M | 2.90M | 17.6M | 2.17M | 3.05M | 5.31M | 910K | 6.31M |
Every figure is extracted from Ernexa Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.